AstraZeneca announces state-of-the-art facility in Rockville

AstraZeneca is investing $300 million in a state-of-the-art facility in Rockville, the company announced Tuesday. The facility is part of the launch of its life-saving cell therapy platforms in the United States for critical cancer trials and future commercial supply. It is expected to create more than 150 new highly-skilled jobs to initially focus on manufacturing T-cell therapies to enable clinical trials to be conducted around the world.